Skip to main content
TipRanks
Go Ultimate75% OFF

Envoy Medical (COCH) Stock Price & Analysis

127 Followers

COCH Stock Chart & Stats

$6.73-$0.14(-2.04%)
At close: 4:00 PM EST
$6$6.5$7$7.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$6.71 - $7.13
52-Week Range
$3.62 - $9.53
Previous Close
$6.87
Volume
N/A
Average Volume (3M)
27.48K
Market Cap
$53.20M
Enterprise Value
$57.28M
Total Cash (Recent Filing)
$14.57M
Total Debt (Recent Filing)
$777.00K
Price to Earnings (P/E)
―
Beta
0.29
Next Earnings
Apr 06, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Differentiation

Acclaim’s fully implanted design could address usability and lifestyle limitations associated with external hearing components. Its differentiated architecture, rechargeable battery, and compatibility with earbuds may support clinician and patient interest if clinical and regulatory milestones are achieved.

Clinical And Regulatory Progress

Full pivotal-trial enrollment and progress on modular PMA submissions represent meaningful execution milestones for an investigational device. Continued progress reduces development uncertainty and creates a clearer path toward potential commercialization, although FDA review and final data remain outstanding.

Addressable Market

The stated market opportunity provides substantial room for long-term adoption if Acclaim receives approval and gains clinical acceptance. Low penetration among estimated adult candidates suggests the category could expand materially, giving Envoy a large demand pool to pursue beyond its current small revenue base.

Bears Say

Weak Revenue And Profitability

Envoy currently generates very little revenue relative to its development cost structure, and negative gross profit shows that existing sales do not yet cover product costs. The resulting losses limit internally funded growth and leave successful commercialization essential to improving earnings power.

Cash Burn And Capital Weakness

Persistent cash consumption alongside negative shareholders’ equity indicates limited financial flexibility for an early-stage medical-device company. Funding the clinical program, regulatory work, hiring, and facility expansion may require continued external capital, potentially constraining strategic choices.

Approval And Commercialization Risk

Acclaim cannot yet support broad commercial adoption because FDA approval has not been granted and the full clinical database remains incomplete. Delayed approval or additional regulatory requirements could postpone revenue scale-up while Envoy continues funding development and commercialization preparations.

Envoy Medical News

COCH FAQ

What was Envoy Medical’s price range in the past 12 months?
Envoy Medical lowest stock price was $3.62 and its highest was $9.53 in the past 12 months.
What is Envoy Medical’s market cap?
Envoy Medical’s market cap is $53.20M.
When is Envoy Medical’s upcoming earnings report date?
Envoy Medical’s next earnings report is estimated for Apr 06, 2027 (not yet confirmed), which is in 138 days.
How were Envoy Medical’s earnings last quarter?
Envoy Medical released its earnings results on Nov 05, 2026. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.67 by $0.17.
Is Envoy Medical overvalued?
According to Wall Street analysts Envoy Medical’s price is currently Undervalued.
Does Envoy Medical pay dividends?
Envoy Medical does not currently pay dividends.
What is Envoy Medical’s EPS estimate?
Envoy Medical’s EPS estimate is -0.65.
How many shares outstanding does Envoy Medical have?
Envoy Medical has 7,744,488 shares outstanding.
What happened to Envoy Medical’s price movement after its last earnings report?
Envoy Medical reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.67. Following the earnings report the stock price went down -0.281%.
Which hedge fund is a major shareholder of Envoy Medical?
Hedge funds hold Envoy Medical shares: the largest hedge-fund position in Envoy Medical is 71,887,525 shares, and hedge funds decreased their holdings by 4.2K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology